GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Ovid Technologies (Wolters Kluwer Health)  (14)
  • 2015-2019  (14)
Material
Publisher
  • Ovid Technologies (Wolters Kluwer Health)  (14)
Person/Organisation
Language
Years
  • 2015-2019  (14)
Year
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    The Hepatic Steatosis Index Is Not Accurate in Predicting the Presence of Fatty Liver Disease in Patients With Hepatitis C Who Achieve Sustained Virologic Response : 927
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  American Journal of Gastroenterology Vol. 113, No. Supplement ( 2018-10), p. S518-
    Details
    In: American Journal of Gastroenterology, Ovid Technologies (Wolters Kluwer Health), Vol. 113, No. Supplement ( 2018-10), p. S518-
    Type of Medium: Online Resource
    ISSN: 0002-9270
    URL: Article
    DOI: 10.14309/00000434-201810001-00927
    RVK:
    XA 18920
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    994 The Performance of the NAFLD Fibrosis Score in Hispanics With Type 2 Diabetes and Biopsy-Proven NAFLD
    Ovid Technologies (Wolters Kluwer Health) ; 2019
    In:  American Journal of Gastroenterology Vol. 114, No. 1 ( 2019-10), p. S578-S578
    Details
    In: American Journal of Gastroenterology, Ovid Technologies (Wolters Kluwer Health), Vol. 114, No. 1 ( 2019-10), p. S578-S578
    Abstract: In patients with nonalcoholic fatty liver disease, Hispanic ethnicity and the presence of type 2 diabetes mellitus (T2DM) are associated with advanced fibrosis (AF). The NAFLD fibrosis score (NFS) is a noninvasive test that has been validated to predict AF but was originally developed in mainly a Caucasian population. The aim of our study was to assess the performance of NFS in Hispanic patients with T2DM and biopsy proven NAFLD METHODS: This was a single institutional study in south Texas. Using ICD 9/ ICD 10 codes, a retrospective chart review between 2010–2017 identified 55,670 patients with T2DM between ages 18–80. 479 out of 55,670 patients had a liver biopsy. The stage of liver fibrosis was scored from F0 to F4 with (F0-2) defined as early fibrosis and (F3-4) as advanced fibrosis (AF). NFS was calculated and patients were divided into three groups: low score ( 〈 -1.45), intermediate score ( -1.45-0.676) and high score consistent with advance fibrosis ( 〉 0.676). Analysis was performed using Stata IC 15. A P value 〈 0.05 was considered statistically significant. Area under the ROC curve (AUC) analysis was done to determine NFS accuracy RESULTS: After excluding patients with missing data to calculate NFS and those with liver transplant, total of 311 patients were included in the study. The mean age was 55.15 ± 9 years, 55.31% were females, mean BMI 33.16 ± 7.9 kg/m2, mean AST 45.56 ± 44.78 U/L, ALT 52.03 ± 38.75 U/L, albumin 3.44 ± 0.60 g/dl, platelets 203.97 ± 84.61 KuL, and the mean NFS was 0.627 ± 1.78. 40% of the patients (125 out of 311) had AF proven by liver biopsy. AF was more predominant among females (43% vs 35%). AUC for NFS to predict AF was 0.73, SE 0.02, 95% CL [0.68-0.79], P 〈 0.001. At the low cutoff point; sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 97%, 11 %, 42 % and 78%, respectively and 67%,72%, 61% and 76% at the high cutoff point ( 〉 0.676). Interestingly, 47% of the cohort was in the intermediate score, 24% of the intermediate group had AF (F3-4) vs 76 % had early fibrosis (F0-2) CONCLUSION: NFS had a fair diagnostic accuracy for predicting the presence of AF in Hispanic patients with NAFLD and T2DM with AUC of 0.73. A large percentage of our cohort was in the intermediate zone indicating the need for sequential testing with other noninvasive tests to improve accuracy
    Type of Medium: Online Resource
    ISSN: 0002-9270 , 1572-0241
    URL: Article
    DOI: 10.14309/01.ajg.0000593512.60232.a8
    RVK:
    XA 18920
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2019
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
    Ovid Technologies (Wolters Kluwer Health) ; 2015
    In:  Transplantation Direct Vol. 1, No. 6 ( 2015-07), p. 1-5
    Details
    In: Transplantation Direct, Ovid Technologies (Wolters Kluwer Health), Vol. 1, No. 6 ( 2015-07), p. 1-5
    Type of Medium: Online Resource
    ISSN: 2373-8731
    URL: Article
    DOI: 10.1097/TXD.0000000000000531
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2015
    detail.hit.zdb_id: 2890276-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Predictors of Mortality in the Critically Ill Cirrhotic Patient: Is the Model for End-Stage Liver Disease Enough?
    Ovid Technologies (Wolters Kluwer Health) ; 2017
    In:  Journal of the American College of Surgeons Vol. 224, No. 3 ( 2017-03), p. 276-282
    Details
    In: Journal of the American College of Surgeons, Ovid Technologies (Wolters Kluwer Health), Vol. 224, No. 3 ( 2017-03), p. 276-282
    Type of Medium: Online Resource
    ISSN: 1072-7515
    URL: Article
    DOI: 10.1016/j.jamcollsurg.2016.11.005
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2017
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort
    Ovid Technologies (Wolters Kluwer Health) ; 2016
    In:  Hepatology Vol. 64, No. 6 ( 2016-12), p. 1969-1977
    Details
    In: Hepatology, Ovid Technologies (Wolters Kluwer Health), Vol. 64, No. 6 ( 2016-12), p. 1969-1977
    Abstract: Chronic liver disease (CLD) and cirrhosis are major sources of morbidity and mortality in the United States. Little is known about the epidemiology of these two diseases in ethnic minority populations in the United States. We examined the prevalence of CLD and cirrhosis by underlying etiologies among African Americans, Native Hawaiians, Japanese Americans, Latinos, and whites in the Multiethnic Cohort. CLD and cirrhosis cases were identified using Medicare claims between 1999 and 2012 among the fee‐for‐service participants (n = 106,458). We used International Classification of Diseases Ninth Revision codes, body mass index, history of diabetes mellitus, and alcohol consumption from questionnaires to identify underlying etiologies. A total of 5,783 CLD (3,575 CLD without cirrhosis and 2,208 cirrhosis) cases were identified. The prevalence of CLD ranged from 3.9% in African Americans and Native Hawaiians to 4.1% in whites, 6.7% in Latinos, and 6.9% in Japanese. Nonalcoholic fatty liver disease (NAFLD) was the most common cause of CLD in all ethnic groups combined (52%), followed by alcoholic liver disease (21%). NAFLD was the most common cause of cirrhosis in the entire cohort. By ethnicity, NAFLD was the most common cause of cirrhosis in Japanese Americans, Native Hawaiians, and Latinos, accounting for 32% of cases. Alcoholic liver disease was the most common cause of cirrhosis in whites (38.2%), while hepatitis C virus was the most common cause in African Americans (29.8%). Conclusions: We showed racial/ethnic variations in the prevalence of CLD and cirrhosis by underlying etiology; NAFLD was the most common cause of CLD and cirrhosis in the entire cohort, and the high prevalence of NAFLD among Japanese Americans and Native Hawaiians is a novel finding, warranting further studies to elucidate the causes. (H epatology 2016;64:1969‐1977)
    Type of Medium: Online Resource
    ISSN: 0270-9139 , 1527-3350
    URL: Article
    DOI: 10.1002/hep.28677
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2016
    detail.hit.zdb_id: 1472120-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells
    Ovid Technologies (Wolters Kluwer Health) ; 2017
    In:  Hepatology Vol. 65, No. 4 ( 2017-04), p. 1249-1266
    Details
    In: Hepatology, Ovid Technologies (Wolters Kluwer Health), Vol. 65, No. 4 ( 2017-04), p. 1249-1266
    Abstract: Prohibitin 1 (PHB1) is best known as a mitochondrial chaperone, and its role in cancer is conflicting. Mice lacking methionine adenosyltransferase α1 (MATα1) have lower PHB1 expression, and we reported that c‐MYC interacts directly with both proteins. Furthermore, c‐MYC and MATα1 exert opposing effects on liver cancer growth, prompting us to examine the interplay between PHB1, MATα1, and c‐MYC and PHB1's role in liver tumorigenesis. We found that PHB1 is highly expressed in normal hepatocytes and bile duct epithelial cells and down‐regulated in most human hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). In HCC and CCA cells, PHB1 expression correlates inversely with growth. PHB1 and MAT1A positively regulate each other's expression, whereas PHB1 negatively regulates the expression of c‐MYC, MAFG, and c‐MAF. Both PHB1 and MATα1 heterodimerize with MAX, bind to the E‐box element, and repress E‐box promoter activity. PHB1 promoter contains a repressive E‐box element and is occupied mainly by MAX, MNT, and MATα1 in nonmalignant cholangiocytes and noncancerous tissues that switched to c‐MYC, c‐MAF, and MAFG in cancer cells and human HCC/CCA. All 8‐month‐old liver‐specific Phb1 knockout mice developed HCC, and one developed CCA. Five‐month‐old Phb1 heterozygotes, but not Phb1 flox mice, developed aberrant bile duct proliferation; and one developed CCA 3.5 months after left and median bile duct ligation. Phb1 heterozygotes had a more profound fall in the expression of glutathione synthetic enzymes and higher hepatic oxidative stress following left and median bile duct ligation. Conclusion : We have identified that PHB1, down‐regulated in most human HCC and CCA, heterodimerizes with MAX to repress the E‐box and positively regulates MAT1A while suppressing c‐MYC , MAFG , and c‐MAF expression; in mice, reduced PHB1 expression predisposes to the development of cholestasis‐induced CCA. (H epatology 2017;65:1249‐1266).
    Type of Medium: Online Resource
    ISSN: 0270-9139 , 1527-3350
    URL: Article
    DOI: 10.1002/hep.28964
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2017
    detail.hit.zdb_id: 1472120-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Role of aramchol in steatohepatitis and fibrosis in mice
    Ovid Technologies (Wolters Kluwer Health) ; 2017
    In:  Hepatology Communications Vol. 1, No. 9 ( 2017-11), p. 911-927
    Details
    In: Hepatology Communications, Ovid Technologies (Wolters Kluwer Health), Vol. 1, No. 9 ( 2017-11), p. 911-927
    Abstract: Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD) that sets the stage for further liver damage. The mechanism for the progression of NASH involves multiple parallel hits, including oxidative stress, mitochondrial dysfunction, inflammation, and others. Manipulation of any of these pathways may be an approach to prevent NASH development and progression. Arachidyl‐amido cholanoic acid (Aramchol) is presently in a phase IIb NASH study. The aim of the present study was to investigate Aramchol's mechanism of action and its effect on fibrosis using the methionine‐ and choline‐deficient (MCD) diet model of NASH. We collected liver and serum from mice fed an MCD diet containing 0.1% methionine (0.1MCD) for 4 weeks; these mice developed steatohepatitis and fibrosis. We also collected liver and serum from mice receiving a control diet, and metabolomes and proteomes were determined for both groups. The 0.1MCD‐fed mice were given Aramchol (5 mg/kg/day for the last 2 weeks), and liver samples were analyzed histologically. Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD‐fed mice. Aramchol down‐regulated stearoyl‐coenyzme A desaturase 1, a key enzyme involved in triglyceride biosynthesis and the loss of which enhances fatty acid β‐oxidation. Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and the GSH/oxidized GSH ratio, the main cellular antioxidant that maintains intracellular redox status. Comparison of the serum metabolomic pattern between 0.1MCD‐fed mice and patients with NAFLD showed a substantial overlap. Conclusion : Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing stearoyl‐coenyzme A desaturase 1 and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. We also demonstrated that the 0.1MCD model resembles the metabolic phenotype observed in about 50% of patients with NAFLD, which supports the potential use of Aramchol in NASH treatment. ( Hepatology Communications 2017;1:911–927)
    Type of Medium: Online Resource
    ISSN: 2471-254X , 2471-254X
    URL: Article
    DOI: 10.1002/hep4.1107
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2017
    detail.hit.zdb_id: 2881134-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  Hepatology Communications Vol. 2, No. 3 ( 2018-03), p. 285-298
    Details
    In: Hepatology Communications, Ovid Technologies (Wolters Kluwer Health), Vol. 2, No. 3 ( 2018-03), p. 285-298
    Abstract: Insulin resistance is a key risk factor in the progression of nonalcoholic fatty liver disease (NAFLD) and may lead to liver fibrosis. Natural killer (NK) cells are thought to exert an antifibrotic effect through their killing of activated hepatic stellate cells (HSCs). Here, we investigated how the interplay between NK cells and HSCs are modified by insulin resistance in NAFLD. Fresh peripheral blood NK cells (clusters of differentiation [CD]56 dim , CD16 + ) were collected from 22 healthy adults and 72 patients with NAFLD not currently taking any medications and without signs of metabolic syndrome. NK cells were assessed for insulin receptor expressions and cytotoxic activity when cultured in medium with HSCs. Fibrosis severities in patients with NAFLD were correlated linearly with elevated serum proinflammatory cytokine expression and insulin resistance severity. At the same time, fibrosis severities inversely correlated with insulin receptor expressions on NK cells as well as with their cytotoxic activities determined by CD107a by flow cytometry. NK cells from donors exhibiting severe fibrosis and insulin resistance exhibited significant mammalian target of rapamycin and extracellular signal-regulated kinase depletion (through NK cell western blot quantitation), increased apoptosis, and failure to attenuate HSC activation in vitro . While exposure to insulin stimulated the cytotoxic activity of healthy NK cells, rapamycin prevented this effect and reduced NK insulin receptor expressions. Conclusion : Elevated insulin levels in F1 and F2 fibrosis enhances NK cell cytotoxic activity toward HSCs and prevents fibrosis progression by insulin receptors and downstream mammalian target of rapamycin and extracellular signal-regulated kinase pathways. At more advanced stages of insulin resistance (F3 and F4 fibrosis), impaired NK cell activity rooted in low insulin receptor expression and or low serum insulin levels could further deteriorate fibrosis and may likely lead to cirrhosis development. ( Hepatology Communications 2018;2:285-298)
    Type of Medium: Online Resource
    ISSN: 2471-254X
    URL: Article
    DOI: 10.1002/hep4.1146
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    detail.hit.zdb_id: 2881134-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  Hepatology Communications Vol. 2, No. 7 ( 2018-07), p. 807-820
    Details
    In: Hepatology Communications, Ovid Technologies (Wolters Kluwer Health), Vol. 2, No. 7 ( 2018-07), p. 807-820
    Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease worldwide and includes a broad spectrum of histologic phenotypes, ranging from simple hepatic steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). While liver biopsy is the reference gold standard for NAFLD diagnosis and staging, it has limitations due to its sampling variability, invasive nature, and high cost. Thus, there is a need for noninvasive biomarkers that are robust, reliable, and cost effective. In this study, we measured 540 lipids and amino acids in serum samples from biopsy‐proven subjects with normal liver (NL), NAFL, and NASH. Using logistic regression analysis, we identified two panels of triglycerides that could first discriminate between NAFLD and NL and second between NASH and NAFL. These noninvasive tests were compared to blinded histology as a reference standard. We performed these tests in an original cohort of 467 patients with NAFLD (90 NL, 246 NAFL, and 131 NASH) that was subsequently validated in a separate cohort of 192 patients (7 NL, 109 NAFL, 76 NASH). The diagnostic performances of the validated tests showed an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.88 ± 0.05, 0.94, and 0.57, respectively, for the discrimination between NAFLD and NL and 0.79 ± 0.04, 0.70, and 0.81, respectively, for the discrimination between NASH and NAFL. When the analysis was performed excluding patients with glucose levels 〉 136 mg/dL, the area under the receiver operating characteristic curve for the discrimination between NASH and NAFL increased to 0.81 ± 0.04 with sensitivity and specificity of 0.73 and 0.80, respectively. Conclusion: The assessed noninvasive lipidomic serum tests distinguish between NAFLD and NL and between NASH and NAFL with high accuracy. ( Hepatology Communications 2018;2:807‐820)
    Type of Medium: Online Resource
    ISSN: 2471-254X , 2471-254X
    URL: Article
    DOI: 10.1002/hep4.1188
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    detail.hit.zdb_id: 2881134-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Trends of Awareness of Non-Alcoholic Fatty Liver Disease, Alcoholic Liver Disease and Both Fatty Liver Diseases (BAFLD) Using National Health and Nutrition Examination Survey : 836
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  American Journal of Gastroenterology Vol. 113, No. Supplement ( 2018-10), p. S465-
    Details
    In: American Journal of Gastroenterology, Ovid Technologies (Wolters Kluwer Health), Vol. 113, No. Supplement ( 2018-10), p. S465-
    Type of Medium: Online Resource
    ISSN: 0002-9270
    URL: Article
    DOI: 10.14309/00000434-201810001-00836
    RVK:
    XA 18920
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...